Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.55 |
| ▸ | NPY1R | P25929 | 7/20 | 0.55 |
| ▸ | NPY2R | P49146 | 5/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.55 |
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.50 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29813882 | 0.86 | OPRK1 (0.44) | NPY4RNPY1RNPY2RNPY5RNMUR2 | |
| SCHEMBL30293724 | 0.85 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RNMUR2 | |
| SCHEMBL30689267 | 0.84 | OPRK1 (0.59) | NPY4RNPY1RNPY2RNPY5RNMUR2 | |
| SCHEMBL18176610 | 0.84 | OPRK1 (0.63) | NPY4RNPY1RNPY2RNPY5RNMUR2 | |
| SCHEMBL30634738 | 0.84 | NMUR2 (0.56) | NPY4RNPY1RNPY2RNPY5RNMUR2 | |
| SCHEMBL29972993 | 0.84 | NMUR2 (0.60) | NPY4RNPY1RNPY2RNPY5RNMUR2 | |
| SCHEMBL9852750 | 0.83 | NPY4R (0.58) | NPY4RNPY1RNPY2RNPY5RNMUR2 | |
| SCHEMBL22288702 | 0.83 | KISS1R (0.57) | — | |
| SCHEMBL22288705 | 0.83 | KISS1R (0.57) | — | |
| SCHEMBL8876493 | 0.83 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672779-B2 | Modulators of GTPases and their use | UNM RAINFOREST INNOVATIONS (US) | 2023-06-13 | — | — | US | claimed |
| EP-4440703-A1 | HETEROCYCLIC COMPOUNDS AS GCN2 AND PERK KINASE INHIBITORS | Deciphera Pharmaceuticals, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-4247795-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023102228-A1 | HETEROCYCLIC COMPOPUNDS AS GCN2 AND PERK KINASE INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-08 | — | — | WO | disclosed |
| US-11591298-B2 | Bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2022109001-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220143183-A1 | PHOTOSWITCHABLE PROTACS AND SYNTHESIS AND USES THEREOF | NEW YORK UNIVERSITY | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591298-B2 | Bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use | SQSTM1, UACA, ATG7 | NPY4R 3780/4885NPY1R 2720/4885NPY2R 2634/4885 |
| US-20220143183-A1 | PHOTOSWITCHABLE PROTACS AND SYNTHESIS AND USES THEREOF | MDM2, UBE3C, CUL1 | NPY4R 4581/4885NPY1R 4524/4885NPY2R 4670/4885 |
| US-11672779-B2 | Modulators of GTPases and their use | CDC42, RAC1, ROCK1 | NPY4R 3622/4885NPY1R 2517/4885NPY2R 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.